VP, Head of Medicinal Chemistry
Brad brings over 30 years of industrial experience in drug discovery and early clinical development to Cogent with an emphasis on oncology research. As a leader of multidisciplinary teams, Brad has managed numerous projects from target selection through candidate nomination and IND filing. Notably, Brad was the project leader for the Array Biopharma/Mirati Therapeutics collaboration that resulted in the KRASG12C Ph3 asset MRTX849 and the KRASG12D inhibitor MRTX1133. Prior to Cogent, Brad was responsible for the progression of the brain penetrant BRAF inhibitor PF-07284890 and the SHP inhibitor PF-07284892 under Pfizer which are currently in clinical trials. Prior to Pfizer and a 20-year stint at Array Biopharma, Brad gained experience as a medicinal chemist at BASF Bioresearch and Novartis. Brad has a BS in biochemistry from The Ohio State University and an MS in medicinal chemistry from Northeastern University. Brad enjoys entertaining and exploring Denver with his wife and two children. When the Ohio State Buckeyes are not on television Brad can be found outdoors hiking, biking and fly fishing.